HZNP : Summary for Horizon Pharma plc - Yahoo Finance

U.S. Markets closed

Horizon Pharma plc (HZNP)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.83-0.20 (-1.33%)
At close: 4:00 PM EST
People also watch:
DEPORDUSCLVSSRPTJUNO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close15.03
Open14.85
Bid14.70 x 500
Ask14.99 x 200
Day's Range14.65 - 15.62
52 Week Range13.05 - 23.44
Volume10,314,508
Avg. Volume3,594,726
Market Cap2.39B
Beta1.13
PE Ratio (TTM)-178.67
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Here’s Our Take On Horizon Pharma PLC (HZNP)’s Fall Out And Regeneron Pharmaceuticals Inc (REGN)’s EMA Hit
    Insider Monkey12 hours ago

    Here’s Our Take On Horizon Pharma PLC (HZNP)’s Fall Out And Regeneron Pharmaceuticals Inc (REGN)’s EMA Hit

    Thursday was a big day for two companies, in two very different ways, in the biotech space. News out of the Horizon Pharma PLC (NASDAQ:HZNP) camp initiated a major selloff in the company, while an FDA announcement regarding Regeneron Pharmaceuticals Inc (NASDAQ:REGN) didn’t have an equivalent impact to the upside, but it did set the […]

  • Capital Cube14 hours ago

    ETFs with exposure to Horizon Pharma Plc : December 9, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Horizon Pharma Plc Here are 5 ETFs with the largest exposure to HZNP-US. Comparing the performance and risk of Horizon Pharma Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails
    Zacks18 hours ago

    Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails

    Horizon Pharma (HZNP) has decided to discontinue the development of Actimmune for Friedreich's ataxia after a phase III study failed to meet key endpoints.